Bristol-Myers Squibb Co at Truist Securities Life Sciences Summit (May Series) Transcript
Good morning, everyone. I'm Greg Gilbert. I cover pharmaceuticals here at Truist. I'm fortunate to be hosting this fireside meeting with Bristol-Myers Squibb.
Before we begin, I need to read the following disclaimer. This call, this meeting is arranged by Truist Securities Research, produced by institutional investors and issuer clients as defined by FINRA. If you are not an institutional investor or issuer, please disconnect at this time. For required disclosures, please see our website at truistsecurities.com or our equity research library.
On today's session, very happy to have with us Adam Lenkowsky, SVP and GM of Oncology, Immunology and Cardiovascular as well as Winselow Tucker, SVP and GM of U.S. Hematology. Thank you, gentlemen, very much for joining me. Thank you also to our Truist investor clients that are watching now or later.
Adam and Winselow , thank you again for joining us. I'd love to ask you to provide a little bit of background on yourselves to give us a sense of what you did before
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |